SequelSEC

Adaptimmune Therapeutics PLC ADAPY

Biological Products, (No Diagnostic Substances) · CIK 0001621227 · Fiscal year ends 1231

Revenue
$65.08M
Fiscal year ended 2025-06-30
Operating income
-$164.22M
Fiscal year ended 2025-06-30
Free cash flow
-$191.67M
Fiscal year ended 2025-06-30

Valuation, from the filing

Public float$230.88MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-06-30
Float per share$0.15Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity19.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2024-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin100.0%93th
Revenue YoY growth195.3%88th
CapEx / revenue0.5%13th
Long-term debt / equity4.24x85th
SBC / revenue6.8%16th
Operating margin-38.6%73th
FCF margin-41.6%71th
Net margin-39.8%71th
R&D / revenue83.7%30th
Current ratio2.92x35th

Adaptimmune Therapeutics PLC (ADAPY) reported revenue of $65.08M and net income of -$169.76M for the fiscal year ended 2025-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Adaptimmune Therapeutics PLC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Adaptimmune Therapeutics PLC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-30
Revenue$65.08M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$164.22M
Net income-$169.76M
Research & development$125.24M
Weighted-average diluted sharesUnavailable
Pretax income-$166.04M
Income tax expense$3.71M
Diluted EPSUnavailable
Selling, general & administrative$90.21M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Adaptimmune Therapeutics PLC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-30
Cash & equivalents$26.06M
Total assets$130.63M
Current assets$78.12M
Total liabilities$201.59M
Current liabilities$51.51M
Total equity incl. NCI-$70.96M
Temporary (mezzanine) equityUnavailable
Inventory$11.41M
Accounts receivable$9.31M
GoodwillUnavailable
Long-term debt$25.68M
Accounts payable$9.42M

Cash flow

Adaptimmune Therapeutics PLC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-30
Operating cash flow-$190.03M
Capital expenditures$1.64M
Investing cash flow$1.79M
Financing cash flow$1.34M
Net change in cash-$186.90M
Stock-based compensation$7.88M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Adaptimmune Therapeutics PLC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-06-30
Free cash flow-$191.67M
Gross marginUnavailable
Operating margin-252.3%
FCF margin-294.5%
SBC / revenue12.1%
Current ratio1.52x
Revenue YoY growth-54.0%
Net margin-260.8%
R&D / revenue192.4%
CapEx / revenue2.5%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ADAPY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-13View SEC filing
10-K · Filed 2025-03-24View SEC filing
10-Q · Filed 2024-11-13View SEC filing
10-Q · Filed 2024-08-12View SEC filing
10-Q · Filed 2024-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.